Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celgene Corp Updates On FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance


Thursday, 24 Oct 2013 07:31am EDT 

Celgene Corp announced that for fiscal 2013, it expects total net product sales to exceed $6.200 billion, Net Product Sales are expected to be in the mid-to-upper end of the range of $4.200 billion to $4.300 billion ,adjusted diluted EPS guidance is raised to a range of $5.90 to $5.95 from the previous range of $5.80 to $5.90 and GAAP diluted EPS is expected to be in the range of $3.77 to $3.90. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $6.367 billion and EPS of $5.98 for fiscal 2013. 

Company Quote

88.34
0.61 +0.70%
30 Jul 2014